Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torii Pharmaceutical Co Ltd

https://www.torii.co.jp/en

Latest From Torii Pharmaceutical Co Ltd

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

Approvals Rare Diseases

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.

Financing Artificial Intelligence

Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy

Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.

Deals Business Strategies

Roxadustat Stacks Up To Darbepoietin In Non-Dialysis Anemia

Astellas’s oral HIF-PH inhibitor shows non-inferiority to one established ESA in head-to-head trial and while there were cardiovascular benefits, the picture is complex.

Clinical Trials Blood & Coagulation Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register